罗格列酮对2型糖尿病尿微量白蛋白的影响

目的探讨罗格列酮对2型糖尿病尿微量白蛋白的影响。方法对65例2型糖尿病病人随机分成两组，对照组30例，以格列吡嗪为主控制血糖；治疗组35例，在对照组基础上联用罗格列酮每日4mg，监测两组病人尿微量白蛋白水平，分别于6个月及12个月作对照分析。结果糖基化血红蛋白（HbAlc）治疗组下降0．8％，而对照组仅下降0．2％。收缩压与舒张压在治疗组下降幅度较大．但两组对比无统计学意义。治疗组尿微量白蛋白在6个月下降6．9％，与对照组比较无统计学意义，而在12个月下降选23．3％，与对照组相比有统计学意义（P〈0．01）。结论2型糖尿病痛人格列吡嗪联用罗格列酮每日4mg治疗12个月，能明显减少尿微量白蛋白。

Rosiglitazone Improves Microalbuminuria Patients with in Type 2 Diabets Patients

Objective To evaluate the effects of rosiglitazone on microalbuminuria in patients with type 2 diabetes mellitus.Methods Sixty-five patients were randomized into two groups.The 30 subjects in the control group received Glipizide.The 35 subjects in the rosiglitazone group received Glipizide and rosiglitazone 4 mg once a day.Each subject was followed for 12 months.Results Comparing to the baseline, HbA1c in the rosiglitazone group reduced by 0.8% while in the control group it reduced by 0.2%. Both of the systolic blood pressure and diastolic blood pressure in the rosiglitazone group decreased. The differences in reduction of blood pressure between the 2 groups were not statistically significant. After 6 months,treatment with rosiglitazone was followed by 6.9% reductions of microalbuminuria.Meanwhile in the control group the same change occurred.The mean reduction in the rosiglitazone group was 23.3%(P<0.01).Conclusion Glipizide in combination withrosiglitazone 4 mg daily for 12 months reduced microalbuminuria remarkably in patients with type 2 diabetes.